tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2021 Oct 6;1-5.
doi: 10.1080/21645515.2021.1974289. Online ahead of print.
Time and cost of administering COVID-19 mRNA vaccines in the United States
Benjamin Yarnoff[SUP] 1 [/SUP], Steven Bodhaine[SUP] 2 [/SUP], Ed Cohen[SUP] 3 [/SUP], Philip O Buck[SUP] 4 [/SUP]
Affiliations
Abstract
In early 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. In response, two novel messenger RNA (mRNA)-based vaccines: mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) were rapidly developed. A thorough understanding of the differences in workflow requirements between the two vaccines may lead to improved efficiencies and reduced economic burden, both of which are crucial for streamlining vaccine deployment and minimizing wastage. Vaccine administration workflow costs are borne by providers and reimbursed separately from dose acquisition in the United States. Currently, mRNA-1273 and BNT162b2 are the most administered COVID-19 vaccines in the United States. In this study, US-licensed and practicing pharmacists were interviewed to collect data on differences in terms of labor costs associated with the workflows for mRNA-1273 and BNT162b2. Results suggest the cost differential for mRNA-1273 compared to BNT162b2 is -$0.82 (or -$1.01 when assuming volume equivalency). If extrapolated to even just a proportion of the remaining unvaccinated US population, this can amount to significant workflow efficiencies and lower vaccine administration costs. Further, as key differences in the vaccine workflow steps between the two vaccines would be similar in other settings/regions, these findings are likely transferable to health-care systems worldwide.
Keywords: COVID-19; USA; Vaccinology; administration time; health economics; labor cost; mRNA vaccine.
. 2021 Oct 6;1-5.
doi: 10.1080/21645515.2021.1974289. Online ahead of print.
Time and cost of administering COVID-19 mRNA vaccines in the United States
Benjamin Yarnoff[SUP] 1 [/SUP], Steven Bodhaine[SUP] 2 [/SUP], Ed Cohen[SUP] 3 [/SUP], Philip O Buck[SUP] 4 [/SUP]
Affiliations
- PMID: 34613860
- DOI: 10.1080/21645515.2021.1974289
Abstract
In early 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. In response, two novel messenger RNA (mRNA)-based vaccines: mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) were rapidly developed. A thorough understanding of the differences in workflow requirements between the two vaccines may lead to improved efficiencies and reduced economic burden, both of which are crucial for streamlining vaccine deployment and minimizing wastage. Vaccine administration workflow costs are borne by providers and reimbursed separately from dose acquisition in the United States. Currently, mRNA-1273 and BNT162b2 are the most administered COVID-19 vaccines in the United States. In this study, US-licensed and practicing pharmacists were interviewed to collect data on differences in terms of labor costs associated with the workflows for mRNA-1273 and BNT162b2. Results suggest the cost differential for mRNA-1273 compared to BNT162b2 is -$0.82 (or -$1.01 when assuming volume equivalency). If extrapolated to even just a proportion of the remaining unvaccinated US population, this can amount to significant workflow efficiencies and lower vaccine administration costs. Further, as key differences in the vaccine workflow steps between the two vaccines would be similar in other settings/regions, these findings are likely transferable to health-care systems worldwide.
Keywords: COVID-19; USA; Vaccinology; administration time; health economics; labor cost; mRNA vaccine.